Women Respond Well to Daily HIV Prevention Pill

Young women who used pre-exposure prophylaxis (PrEP) for preventing HIV acquisition were willing to take a daily dose, resulting in higher coverage of sex events, higher drug concentrations, and better adherence, researchers reported here. About 80% of women in the trial conducted in South Africa were compliant in taking a daily dose of the combination table of emtricitabine and tenofovir (Truvada) within 7 days of a sexual encounter compared with 70% of participants who were taking the pills twice a week (P=0.002), and compared with 50% of participants who were taking pills in preparation of having sex (P<0.001), said Robert Grant, MD, MPH, of the University of California San Francisco, and colleagues. http://www.medpagetoday.com/MeetingCoverage/IAS/52678?xid=nl_mpt_DHE_2015-07-21&eun=g721819d0r